APA (7th ed.) Citation

Fasching, P. A., Szeto, C., Denkert, C., Benz, S., Weber, K., Spilman, P., . . . Loibl, S. (2023). Inferred immune-cell activity is an independent predictor of HER2-negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. Clinical cancer research, 29(13), . https://doi.org/10.1158/1078-0432.CCR-22-2213

Chicago Style (17th ed.) Citation

Fasching, Peter Andreas, et al. "Inferred Immune-cell Activity Is an Independent Predictor of HER2-negative Breast Cancer Prognosis and Response to Paclitaxel-based Therapy in the GeparSepto Trial." Clinical Cancer Research 29, no. 13 (2023). https://doi.org/10.1158/1078-0432.CCR-22-2213.

MLA (9th ed.) Citation

Fasching, Peter Andreas, et al. "Inferred Immune-cell Activity Is an Independent Predictor of HER2-negative Breast Cancer Prognosis and Response to Paclitaxel-based Therapy in the GeparSepto Trial." Clinical Cancer Research, vol. 29, no. 13, 2023, https://doi.org/10.1158/1078-0432.CCR-22-2213.